The emerging role of T cells in pemphigus vulgaris: a systematic review
- PMID: 35925475
- DOI: 10.1007/s10238-022-00855-8
The emerging role of T cells in pemphigus vulgaris: a systematic review
Abstract
Pemphigus vulgaris is a potential life-threatening autoimmune bullous disorder. The significant role of autoreactive B cells in the pathogenesis of PV has been explained extensively by producing autoantibodies. Recently, attention has been directed toward the role of T cells in the pathogenesis of PV; in other words, the underlying etiology of PV depends on the interaction between T cells and B cells resulting in antibody secretion. Herein, we systematically review the current literature on the emerging role of T cells in PV. To perform this systematic review, an extensive search through EMBASE, PubMed, Scopus, and ISI databases was performed from 1976 through 2021. Articles investigating the function of T cell subgroups in the pathogenesis or treatment of pemphigus vulgaris were included and reviewed. It is evidenced that T cells play a pivotal role in PV pathogenesis. Th1 and Th2 dichotomy including Th1 suppression and Th2 elevation may induce antibody production against desmoglein in keratinocytes. Furthermore, increased level of Th17 and decreased level of regulatory T cells have been detected in PV patients. However, further studies on the exact role of γδ-T cells in PV are required in order to clarify the pathogenesis of PV. T cells and their subtypes can be involved in the pathogenesis of PV. Thus, they can be considered as tentative targets of novel therapies for PV.
Keywords: Immune system; Pemphigus vulgaris; T cell.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Beyond the skin: B cells in pemphigus vulgaris, tolerance and treatment.Br J Dermatol. 2024 Jul 16;191(2):164-176. doi: 10.1093/bjd/ljae107. Br J Dermatol. 2024. PMID: 38504438 Review.
-
Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.Int Immunopharmacol. 2018 Jan;54:131-138. doi: 10.1016/j.intimp.2017.11.005. Epub 2017 Nov 10. Int Immunopharmacol. 2018. PMID: 29132070
-
A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic.Front Immunol. 2025 Jan 21;15:1508129. doi: 10.3389/fimmu.2024.1508129. eCollection 2024. Front Immunol. 2025. PMID: 39906745 Free PMC article.
-
What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review.J Cell Physiol. 2022 Jul;237(7):2825-2837. doi: 10.1002/jcp.30784. Epub 2022 May 26. J Cell Physiol. 2022. PMID: 35616233 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
Focus on pemphigus treatment publications: A bibliometric and visual analysis (1992-2022).Heliyon. 2024 Mar 20;10(7):e28462. doi: 10.1016/j.heliyon.2024.e28462. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38590872 Free PMC article. Review.
References
-
- Schmidt E, Zillikens D. Pemphigoid diseases. The Lancet. 2013;381(9863):320–32.
-
- Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017;3(1):1–18.
-
- David M, Katzenelson V, Hazaz B, Ben-Chetrit A, Sandbank M. Determination of IgG subclasses in patients with pemphigus with active disease and in remission. Arch Dermatol. 1989;125(6):787–90. - PubMed
-
- Saleh MA, Ishii K, Yamagami J, Shirakata Y, Hashimoto K, Amagai M. Pathogenic anti-desmoglein 3 mAbs cloned from a paraneoplastic pemphigus patient by phage display. J Invest Dermatol. 2012;132(4):1141–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical